Cargando...

Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities

Oncogenic mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS) occur in 15%–30% of non-small cell lung cancer (NSCLC). However, despite decades of intensive research, there is still no direct KRAS inhibitor with clinically proven efficacy. Considering its association with poor treatment re...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Acta Biochim Biophys Sin (Shanghai)
Main Authors: Zhang, Jun, Park, Dongkyoo, Shin, Dong M., Deng, Xingming
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2016
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4689161/
https://ncbi.nlm.nih.gov/pubmed/26578706
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/abbs/gmv118
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!